Denali Therapeutics Is A Clinical Stage Biopharmaceutical Company Based In South San Franciscocaliforniathe Company Focuses On Developing Therapies For Neurodegenerative Diseasessuch As Alzheimerae S And Parkinsonae Sas Well As Lysosomal Storage Disorders Like Hunter Syndromedenali Employs Around 422 Professionals And Utilizes Proprietary Blood Brain Barrier Transport Technologies To Meet The Medical Needs Of Patients With Brain Related Disorders Denali S Innovative Approach Includes Four Engineered Transport Vehicle Systemsenzyme Transport Vehicleetv Antibody Transport Vehicleatv Protein Transport Vehicleptv And Oligonucleotide Transport Vehicleotv These Technologies Enable The Delivery Of Various Therapeutic Agents To The Brainthe Company Collaborates With Major Pharmaceutical Partnersincluding Sanofiabbvieand Takedato Enhance The Development Of Its Pipeline Productswhich Include Dnl310 For Hunter Syndrome And Dnl151 For Parkinsonae S Diseasedenali S Mission Is To Advance Therapies That Address The Underlying Causes Of Neurodegenerationemphasizing A Commitment To Rigorous Science And Patient Focused Innovation
